ArticleFrontiers in cardiovascular medicine2025
Clinical characteristics and influencing factors of cardiovascular comorbidities in psoriasis.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Assessments of Wnt/JAK-STAT Signaling Pathway in Relation to Sfrp5 Among Patients with Cardiac Diseases.International journal of molecular sciences · 2025Article
- Commentary: Clinical characteristics and influencing factors of cardiovascular comorbidities in psoriasis-a critical appraisal of causality and shared pathogenesis.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Psoriasis is a chronic inflammatory skin disorder with systemic implications, including an elevated risk of cardiovascular disease (CVD). The interaction between psoriasis severity, metabolic abnormalities, and systemic inflammation may contribute to cardiovascular comorbidities. However, the clinical characteristics and predictors of CVD in psoriasis patients remain incompletely understood. Methods: We conducted a retrospective cohort study of 320 adult patients with psoriasis. Participants were categorized into two groups according to cardiovascular status (psoriasis with CVD vs. psoriasis without CVD). Demographic, clinical, metabolic, and inflammatory parameters were compared. Variable selection was performed using LASSO regression, followed by multivariable logistic regression to identify independent predictors of CVD. Kaplan-Meier curves and Cox proportional hazards models were applied to evaluate survival outcomes. Results: Among 320 psoriasis patients, 88 (27.5%) had cardiovascular comorbidities. Compared with controls, patients with CVD were significantly older, had longer psoriasis duration, higher body mass index, and more severe disease (mean PASI 12.8 vs. 9.7, Discussion: Psoriasis patients with cardiovascular comorbidities demonstrate a distinct clinical and inflammatory profile. Our findings underscore the importance of integrated management, with aggressive control of both psoriasis severity and traditional risk factors to mitigate cardiovascular burden. Future prospective studies should evaluate whether targeted anti-inflammatory therapies can reduce cardiovascular outcomes in psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.